Citizens JMP lowered the firm’s price target on Pharvaris (PHVS) to $52 from $55 and keeps an Outperform rating on the shares. Pharvaris continues to execute on its pivotal hereditary angioedema programs with data from its pivotal RAPIDe-3 trial in acute HAE in Q4 and CHAPTER-3 data in HAE prophylaxis in the second half of 2026, the analyst tells investors in a research note. The firm is impressed with management’s execution with the first Phase 3 data for deucrictibant for on-demand HAE treatment expected next quarter.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris Reports Q2 2025 Financials and Advances Phase 3 Studies
- Pharvaris Raises $201 Million in Successful Offering
- Pharvaris 8.25M share Spot Secondary priced at $20.00
- Pharvaris announces $150M ordinary shares offering
- Pharvaris’s Accelerated Phase 3 Trial Timeline and Market Potential Boost Buy Rating